Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: Systematic review and multiple treatments meta-analysis

BMC Medicine

Volumn 10, Issue , 2012, Pages

  Fretheim, Atle ^a,b   Odgaard Jensen, Jan ^a   Brørs, Odd ^c   Madsen, Steinar ^d   Njølstad, Inger ^e   Norheim, Ole F ^f,g   Svilaas, Arne ^c   Kristiansen, Ivar S ^b   Thürmer, Hanne ^h   Flottorp, Signe ^a,g  

^a NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Norwegian Medicines Agency   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF BERGEN   (Norway)

^h Telemark Hospital   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DILTIAZEM; DOXAZOSIN; ENALAPRIL; FELODIPINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; ISRADIPINE; LACIDIPINE; LISINOPRIL; LOSARTAN; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PINDOLOL; PLACEBO; RESERPINE; TRIAMTERENE; TRICHLORMETHIAZIDE; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; SYSTEMATIC REVIEW; CHEMOPROPHYLAXIS; COMPARATIVE STUDY; INCIDENCE; METHODOLOGY; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CHEMOPREVENTION; HUMANS; INCIDENCE; MYOCARDIAL INFARCTION; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84859327058     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-10-33     Document Type: Article

References (65)

1. World Health Organization The Global Burden Of Disease: 2004 Update 2008, Geneva: WHO, World Health Organization.
2. The World Health Organization World Health Statistics 2008 2008, Geneva: The World Health Organization, The World Health Organization.
3. The World Health Organization The World Health Report 2002 Reducing Risks, Promoting Healthy Lives 2002, Geneva: The World Health Organization, The World Health Organization.
4. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838. 10.1016/0140-6736(90)90944-Z, 1969567.
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527-1535.
6. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665. 10.1136/bmj.b1665, 2684577, 19454737.
7. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?. CMAJ 1999, 161:25-32. 1232645, 10420860.
8. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003, 289:2534-2544. 10.1001/jama.289.19.2534, 12759325.
9. Hypertension: The clinical management of primary hypertension in adults (update) 2011, London: National Clinical Guidelines Centre at the The Royal College of Physicians.
10. ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000, 283:1967-1975. see comment Erratum: JAMA 2002, 288:2976, 10.1001/jama.283.15.1967, 10789664, ALLHAT Collaborative Research Group.
11. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice?. Lancet 2004, 364:1684-1689. 10.1016/S0140-6736(04)17355-8, 15530629.
12. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007, CD002003.
13. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007, 369:201-207. 10.1016/S0140-6736(07)60108-1, 17240286.
14. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011, 171:384-394. 10.1001/archinternmed.2010.427, 21059964.
15. Håheim L, Fretheim A, Brørs O, Kjeldsen SE, Kristiansen IS, Madsen S, Njølstad I, Norheim OF, Ose L, Svilaas A, Flottorp S, Thürmer H. Primærforebygging av hjerte- og karsykdom, med særlig vekt på medikamentelle tiltak 2008, Oslo, Norway: Norwegian Knowledge Centre for the Health Services.
16. Norheim OF, Gjelsvik B, Klemsdal TO, Madsen S, Meland E, Narvesen S, Negard A, Njølstad I, Tonstad S, Ulvin F, Wisløff T. Norway's new principles for primary prevention of cardiovascular disease: age differentiated risk thresholds. BMJ 2011, 343:d3626.
17. Fretheim A, Odgaard-Jensen J, Brørs O, Flottorp S, Kristiansen IS, Njølstad I, Norheim OF, Svilaas A, Thürmer H. Systematic Review and Multiple Treatment Meta-Analysis of Drug-Trials for Hypertension (protocol) PROSPERO 2011:CRD42011001066 Available from [http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42011001066].
18. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2004, NIH Publication No. 04-5230.
19. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev 2009, CD001841.
20. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
21. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001, 323:334-336. 1120936, 11498496.
22. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008, 17:279-301.
23. Dias S, Welton N, Caldwell D, Ades A. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010, 29:932-944. 10.1002/sim.3767, 20213715.
24. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011, 64:401-406. 10.1016/j.jclinepi.2010.07.015, 21208779.
25. Sun M, Zhou H, Jia Z. Prevention and treatment of stroke after hypertension for ten years in Hunan Province. Chinese. Zhonghua Nei Ke Za Zhi 1997, 36:312-314.
26. SHEP Cooperative Research Group Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. SHEP Cooperative Research Group.
27. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980, 69:725-732. 10.1016/0002-9343(80)90438-6, 7001898.
28. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, Hornkvist PE, Pennert K, Tuomilehto J, Wedel H. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987, 5:561-572. 10.1097/00004872-198710000-00009, 2892881.
29. Peart S, Brennan PJ, Broughton P, Dollery C, Hudson MF, Lever AF, Meade TW, Rose GA, Greenberg G, Pocock SJ. Medical Research Council trial of treatment of hypertension in older adults: Principal results. BMJ 1992, 304:405-412. 1995577, 1445513.
30. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck J. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616. 10.1016/S0140-6736(98)05012-0, 10030325.
31. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999, 34:1129-1133.
32. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756. 10.1016/S0140-6736(99)10327-1, 10577635.
33. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. Erratum: JAMA 2003, 289:178, 10.1001/jama.288.23.2981, 12479763, ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
34. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356:359-365. 10.1016/S0140-6736(00)02526-5, 10972367.
35. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G, Ruilope LM. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003, 41:431-436. 10.1161/01.HYP.0000057420.27692.AD, 12623939.
36. LIFE Study Group Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:1004-1010. 10.1016/S0140-6736(02)08090-X, 11937179, LIFE Study Group.
37. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, Johnston CI, Mcneil JJ, Macdonal GJ, Marley JE, Morga TO, West MJ, . Second Australian National Blood Pressure Study Group A comparison of outcomes with angiotensin-converting--enzyme inhibi-tors and diuretics for hypertension in the elderly. N Engl J Med 2003, 348:583-592. 10.1056/NEJMoa021716, 12584366, Second Australian National Blood Pressure Study Group.
38. CONVINCE Research Group Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003, 289:2073-2082. 10.1001/jama.289.16.2073, 12709465, CONVINCE Research Group.
39. Bulpitt CJ, Beckett NS, Cooke J, Dumitrascu DL, Gil-Extremera B, Nachev C, Nunes M, Peters R, Staessen JA, Thijs L, . Hypertension in the Very Elderly Trial Working Group Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003, 21:2409-2417. 10.1097/00004872-200312000-00030, 14654762, Hypertension in the Very Elderly Trial Working Group.
40. Malacco E, Mancia G, Rappelli A, Menotti A, Zuccaro MS, Coppini A. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003, 12:160-167. 10.1080/08037050310009545, 12875478.
41. Suzuki H, Kanno Y. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens Res 2005, 28:307-314. 10.1291/hypres.28.307, 16138560.
42. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, Sato T, Saruta T. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008, 51:393-398. 10.1161/HYPERTENSIONAHA.107.098475, 18172059.
43. Veterans Administration Cooperative Study Group on Antihypertensive Agents Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970, 213:1143-1152. Veterans Administration Cooperative Study Group on Antihypertensive Agents.
44. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, de Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985, 1:1349-1354.
45. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986, 293:1145-1151.
46. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285. 10.1016/0140-6736(91)92589-T, 1682683.
47. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997, 350:757-764. 10.1016/S0140-6736(97)05381-6, 9297994.
48. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008, 358:1887-1898. 10.1056/NEJMoa0801369, 18378519.
49. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Jua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022-2031. 10.1016/S0140-6736(04)16451-9, 15207952.
50. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima N. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007, 369:1431-1439. 10.1016/S0140-6736(07)60669-2, 17467513.
51. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428. 10.1056/NEJMoa0806182, 19052124.
52. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlson J, Nieminen M, O'Brien E, Otergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005, 366:895-906. 10.1016/S0140-6736(05)67185-1, 16154016.
53. Sawada T, Yamada H, Dahlof B, Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009, 30:2461-2469. 10.1093/eurheartj/ehp363, 19723695.
54. The IPPPSH Collaborative Group Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). The IPPPSH Collaborative Group. J Hypertens 1985, 3:379-392. The IPPPSH Collaborative Group.
55. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003, 21:875-886. 10.1097/00004872-200305000-00011, 12714861.
56. Aursnes I, Tvete IF, Gasemyr J, Natvig B. Clinical efficacies of antihypertensive drugs. Scand Cardiovasc J 2003, 37:72-79. 10.1080/14017430310001186, 12775305.
57. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, . the Guideline Development Group Guidelines: management of hypertension: summary of NICE guidance. BMJ 2011, 343:d4891. 10.1136/bmj.d4891, 21868454, the Guideline Development Group.
58. National Collaborating Centre for Chronic Conditions. Hypertension: Management of Hypertension in Adults in Primary Care: Partial Update 2006, London: Royal College of Physicians.
59. Statens Beredning för Medicinsk Utvärdering. Måttligt Förhöjt Blodtryck Uppdatering 2007 2007, Stockholm: Statens beredning för medicinsk utvärdering (SBU).
60. Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 2000, 13:461-467. 10.1016/S0895-7061(99)00215-0, 10826395.
61. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild to moderate essential hypertension--The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens Res 1995, 18:235-244. 10.1291/hypres.18.235, 7584934.
62. Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?. Circulation 2003, 108:2608-2610. 10.1161/01.CIR.0000090572.51900.92, 14638524.
63. Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens (Greenwich) 2005, 7:21-26.
64. World Health Organization Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Total Cardiovascular risk 2007, Geneva: World Health Organization, World Health Organization.
65. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003, 326:1167-1170. 10.1136/bmj.326.7400.1167, 156458, 12775614.